LLY Lilly(Eli) & Co Dashboard

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Company profile

Ticker

LLY

Exchange

NYSE

Website

www.lilly.com/

CEO

David Ricks

Incorporated

Indiana

Location

Indiana

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Warner Chilcott • Abbvie ...

Former names

LILLY ELI & CO, LILLY ELI & CO ET AL

SEC CIK

0000059478

Corporate docs

Articles of Incorporation & Bylaws

IRS number

350470950

LLY stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs

16 Apr 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)

Lilly Requests Revocation Of Emergency Use Authorization For Bamlanivimab Alone To Complete Transition To Bamlanivimab And Etesevimab Together For Treatment Of COVID-19 In The US; Request Not Due To New Safety Concern

16 Apr 21

Eli Lilly and Company (NYSE:LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this request due to the

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead

14 Apr 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)

SciNeuro Pharma Reports Exclusive License Deal With Eli Lilly For Development, Commercialization Of Alpha-Synuclean Targeted Antibody Therapies In Greater China, No Terms Disclosed

14 Apr 21

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug

13 Apr 21

Press releases

Pro users get this 30m faster

Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

16 Apr 21

INDIANAPOLIS, April 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg

Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer

13 Apr 21

INDIANAPOLIS, April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information and digital officer. Rau

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

12 Apr 21

SAN FRANCISCO and SUZHOU, China, April 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes

Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

12 Apr 21

Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting

11 Apr 21

Calendar

17 Feb 21

18 Apr 21

31 Dec 21

Financial summary

Financial statements Chart LLY financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

LLY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Mar 21	Kimberly H Johnson	Common Stock	Grant	Aquire A	No	No	189.16	51	9.65K	51
15 Mar 21	Tai Jackson P	Common Stock	Grant	Aquire A	No	No	189.16	10	1.89K	59,819
15 Mar 21	Alvarez Ralph	Common Stock	Grant	Aquire A	No	No	189.16	58	10.97K	49,459
9 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	211.901	1,726	365.74K	110,302,100
9 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	211.133	7,720	1.63M	110,303,826
9 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	210.278	17,270	3.63M	110,311,546
9 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	209.122	33,243	6.95M	110,328,816
8 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	210.118	60,874	12.79M	110,362,059
8 Mar 21	Lilly Endowment	Common Stock	Sell	Dispose S	No	No	209.29	64,410	13.48M	110,422,933

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

LLY institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

81.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1836	1735	+5.8%
Opened positions	236	139	+69.8%
Closed positions	135	129	+4.7%
Increased positions	638	609	+4.8%
Reduced positions	659	656	+0.5%

13F shares	Current	Prev Q	Change
Total value	132.6B	107.44B	+23.4%
Total shares	785.47M	725.13M	+8.3%
Total puts	4.46M	3.73M	+19.6%
Total calls	4.41M	2.58M	+70.8%
Total put/call ratio	1.0	1.4	-30.0%

Largest owners	Shares	Value	Change
Lilly Endowment	111.13M	$18.76B	0.0%
Vanguard	68.66M	$11.59B	-0.7%
BLK Blackrock	58.81M	$9.93B	-2.7%
PNC PNC Financial Services	52.33M	$8.84B	+2122.0%
Primecap Management	36.76M	$6.21B	-3.2%
STT State Street	33.47M	$5.65B	-4.2%
Wellington Management	33.15M	$5.6B	+30.9%
FMR	25.63M	$4.33B	-14.2%
JPM JPMorgan Chase & Co.	21.52M	$3.63B	+14.2%
State Farm Mutual Automobile Insurance	18.62M	$3.14B	0.0%

Largest transactions	Shares	Bought/sold	Change
PNC PNC Financial Services	52.33M	+49.98M	+2122.0%
Norges Bank	8.67M	+8.67M	NEW
Wellington Management	33.15M	+7.83M	+30.9%
Capital International Investors	11.37M	-4.77M	-29.6%
FMR	25.63M	-4.23M	-14.2%
TROW T. Rowe Price	12.09M	+4.08M	+51.0%
Jennison Associates	1.88M	-2.7M	-59.0%
JPM JPMorgan Chase & Co.	21.52M	+2.67M	+14.2%
IVZ Invesco	6.46M	+1.91M	+41.9%
Two Sigma Advisers	193.42K	-1.89M	-90.7%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AbCellera, advisory, Agener, ALK, Alkem, Almirall, anchored, antagonist, API, Asahi, Ascend, ascending, Ashkenazi, Asian, Attached, attract, attracting, aura, axial, axonal, baicker, bamlanivimab, BePurchased, bertozzi, BI, billing, bioavailable, bisexual, bispecific, Bowfin, BPCIA, build, burdened, Campaign, career, carolyn, ceiling, child, childcare, Citibank, classic, cloud, cohesive, Columbia, compel, compensatory, Congressional, Conjugate, Connecticut, Consent, context, core, coupled, creation, cultivate, custody, CVR, declared, deeply, Deferral, degeneration, deputy, Deutsche, diagnosed, diagnosing, Disarm, dispensing, dispute, distancing, DiversityInc, donald, Donanemab, donation, double, duly, editing, ejection, emphasized, enjoining, ERG, ergonomic, erik, eskew, etesevimab, Ethisphere, EUA, Evox, exacerbate, excellence, explained, export, feedback, feel, Fochon, fostering, foundation, Fournier, fraction, Francisco, French, fyrwald, gangrene, garnered, gay, genetic, goal, grew, hacking, halt, halted, Hampshire, Heart, heightened, hematological, Hematology, HHS, hiring, Hodgkin, home, Hong, honoring, Hopira, hosting, household, HR, HRSA, Hub, Ilya, inapplicable, indirectly, ineffective, Inline, instance, intensify, jackson, Job, jr, juan, Junshi, justifying, kaelin, katherine, kathi, kidney, KIMBERLY, Kong, Latinx, leader, leadership, learning, left, lesbian, LGBTQ, licensure, lifesaving, LillyNow, luciano, lymphoma, Lyumjev, mAb, Macau, Magazine, mainland, markup, marschall, meaningful, Medco, medullary, Membership, MGM, Minister, modality, modest, moral, Mother, Multicultural, Mylan, neurological, Newsweek, NILEX, Nonalcoholic, nondiscrimination, ofPublicly, older, omitted, online, ordinary, overarching, overturned, overturning, Page, Paidper, patching, paused, payroll, Perfect, Petitioner, pharmacology, pool, postponed, potency, presence, presidential, principle, prioritization, protamine, protracted, psychological, purity, queer, question, questioning, recession, recouping, refractory, refund, reimportation, relapsed, remdesivir, remediate, remote, repaid, representation, resource, Retevmo, Retsevmo, revoked, robust, Rochester, runge, RVA, Score, scrutiny, secondary, seifert, SELIC, Semglee, Shanghai, SharesPurchased, shortage, sintilimab, Sitryx, Society, sooner, speed, spread, Stamford, steal, storage, straight, strain, strictly, subset, sued, Suppurativa, switching, tai, Taiwan, talent, talented, TauvidTM, thereunto, thought, threatened, Thrive, top, Toronto, transgender, transient, transmission, travel, treatement, Tripartite, trustee, twelve, Tyvyt, unapproved, underrepresented, undersigned, unemployment, unexpectedly, unfunded, unlawful, unrelated, unsuccessfully, Valueof, video, violate, violated, viral, virtual, vivo, voting, warning, widespread, william, woman, workplace, XBRL, Yuffa, Zagotenemab, zakrowski, Zentiva

Removed: Abasaglar, accelerating, Accountant, Adcirca, Axiron, bacteria, Baxter, beta, body, BPCI, brain, calcitonin, called, cancelable, CGRP, chair, character, CoLucid, compute, concomitantly, CureVac, deficiency, displacement, distinguished, DOJ, earliest, earning, Effient, emission, endocrinology, erode, eroded, exercised, expend, expiring, front, fundamentally, galcanezumab, geography, glucagon, healthy, hormone, Humatrope, Hurricane, hyperactivity, IIb, illustrated, image, imaging, Immunological, injected, injury, inside, installment, insufficient, insurer, irrelevant, Joshua, KeyBioscience, lanabecestat, Maria, McKesson, Medtronic, metabolic, Mine, Missouri, Mutual, Nektar, neurofibrillary, Nipro, NME, Nomination, noncancelable, nonqualified, Notwithstanding, novelty, obsolescence, offered, Ohio, opt, peptide, pet, positron, predetermined, prejudice, protein, provisional, purporting, pursued, Ratify, Reddy, refining, remeasurement, remeasuring, rewarded, sarcoma, Sawai, screening, shut, side, significance, Smiley, soft, statistical, Strafford, stranded, Strattera, structural, study, studying, subcutaneously, suspended, targeted, taxation, testosterone, tissue, tomography, topic, toxicity, tracer, Unresolved, voluntarily

From filing 10-K 2020 FY